The use of magnetic resonance imaging in multiple sclerosis treatment trials

Power calculations for annual lesion load measurement

Paul D. Molyneux, David H. Miller, Massimo Filippi, Tarek Yousry, Ludwig Kappos, Claudio Gasperini, Herman J. Adèr, Frederik Barkhof

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Phase III definitive treatment trials of new multiple sclerosis (MS) therapies now routinely incorporate an annual magnetic resonance imaging protocol, with change in T2-weighted brain lesion load providing an important outcome measure. To date the accepted strategy has been to perform a core imaging protocol on all patients in such studies. The aim of this study was to provide power calculations based on this MRT endpoint. Serial MRI data from 128 patients with either relapsing remitting (RR) or secondary progressive (SP) MS were used to calculate sample size requirements using a repeated measures analysis of variance design. We provide sample size calculations based on various follow-up intervals and effect sizes. Sample sizes for the SPMS cohort were substantially larger than for the RRMS group, reflecting the greater variance in lesion load changes between patients in the SPMS group. With a follow-up of 3 years, we estimate that only 12 and 33 patients per arm are needed to show stabilisation of MRI lesion load in the RRMS and SPMS groups, respectively. Our results suggest that ongoing phase III treatment trials are more than adequately powered to detect even subtle treatment effects, and indicate that incorporating measurements from longer follow-up durations increases power substantially. We conclude that an annual imaging protocol provides a robust and powerful tool for assessing effects on the radiological appearance of the disease process.

Original languageEnglish
Pages (from-to)34-40
Number of pages7
JournalJournal of Neurology
Volume247
Issue number1
Publication statusPublished - 2000

Fingerprint

Multiple Sclerosis
Magnetic Resonance Imaging
Sample Size
Chronic Progressive Multiple Sclerosis
Therapeutics
Analysis of Variance
Outcome Assessment (Health Care)
Brain

Keywords

  • Multiple sclerosis
  • Power calculations
  • Treatment trial

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Molyneux, P. D., Miller, D. H., Filippi, M., Yousry, T., Kappos, L., Gasperini, C., ... Barkhof, F. (2000). The use of magnetic resonance imaging in multiple sclerosis treatment trials: Power calculations for annual lesion load measurement. Journal of Neurology, 247(1), 34-40.

The use of magnetic resonance imaging in multiple sclerosis treatment trials : Power calculations for annual lesion load measurement. / Molyneux, Paul D.; Miller, David H.; Filippi, Massimo; Yousry, Tarek; Kappos, Ludwig; Gasperini, Claudio; Adèr, Herman J.; Barkhof, Frederik.

In: Journal of Neurology, Vol. 247, No. 1, 2000, p. 34-40.

Research output: Contribution to journalArticle

Molyneux, PD, Miller, DH, Filippi, M, Yousry, T, Kappos, L, Gasperini, C, Adèr, HJ & Barkhof, F 2000, 'The use of magnetic resonance imaging in multiple sclerosis treatment trials: Power calculations for annual lesion load measurement', Journal of Neurology, vol. 247, no. 1, pp. 34-40.
Molyneux, Paul D. ; Miller, David H. ; Filippi, Massimo ; Yousry, Tarek ; Kappos, Ludwig ; Gasperini, Claudio ; Adèr, Herman J. ; Barkhof, Frederik. / The use of magnetic resonance imaging in multiple sclerosis treatment trials : Power calculations for annual lesion load measurement. In: Journal of Neurology. 2000 ; Vol. 247, No. 1. pp. 34-40.
@article{cab3f60c63164172962eafff20d76443,
title = "The use of magnetic resonance imaging in multiple sclerosis treatment trials: Power calculations for annual lesion load measurement",
abstract = "Phase III definitive treatment trials of new multiple sclerosis (MS) therapies now routinely incorporate an annual magnetic resonance imaging protocol, with change in T2-weighted brain lesion load providing an important outcome measure. To date the accepted strategy has been to perform a core imaging protocol on all patients in such studies. The aim of this study was to provide power calculations based on this MRT endpoint. Serial MRI data from 128 patients with either relapsing remitting (RR) or secondary progressive (SP) MS were used to calculate sample size requirements using a repeated measures analysis of variance design. We provide sample size calculations based on various follow-up intervals and effect sizes. Sample sizes for the SPMS cohort were substantially larger than for the RRMS group, reflecting the greater variance in lesion load changes between patients in the SPMS group. With a follow-up of 3 years, we estimate that only 12 and 33 patients per arm are needed to show stabilisation of MRI lesion load in the RRMS and SPMS groups, respectively. Our results suggest that ongoing phase III treatment trials are more than adequately powered to detect even subtle treatment effects, and indicate that incorporating measurements from longer follow-up durations increases power substantially. We conclude that an annual imaging protocol provides a robust and powerful tool for assessing effects on the radiological appearance of the disease process.",
keywords = "Multiple sclerosis, Power calculations, Treatment trial",
author = "Molyneux, {Paul D.} and Miller, {David H.} and Massimo Filippi and Tarek Yousry and Ludwig Kappos and Claudio Gasperini and Ad{\`e}r, {Herman J.} and Frederik Barkhof",
year = "2000",
language = "English",
volume = "247",
pages = "34--40",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "1",

}

TY - JOUR

T1 - The use of magnetic resonance imaging in multiple sclerosis treatment trials

T2 - Power calculations for annual lesion load measurement

AU - Molyneux, Paul D.

AU - Miller, David H.

AU - Filippi, Massimo

AU - Yousry, Tarek

AU - Kappos, Ludwig

AU - Gasperini, Claudio

AU - Adèr, Herman J.

AU - Barkhof, Frederik

PY - 2000

Y1 - 2000

N2 - Phase III definitive treatment trials of new multiple sclerosis (MS) therapies now routinely incorporate an annual magnetic resonance imaging protocol, with change in T2-weighted brain lesion load providing an important outcome measure. To date the accepted strategy has been to perform a core imaging protocol on all patients in such studies. The aim of this study was to provide power calculations based on this MRT endpoint. Serial MRI data from 128 patients with either relapsing remitting (RR) or secondary progressive (SP) MS were used to calculate sample size requirements using a repeated measures analysis of variance design. We provide sample size calculations based on various follow-up intervals and effect sizes. Sample sizes for the SPMS cohort were substantially larger than for the RRMS group, reflecting the greater variance in lesion load changes between patients in the SPMS group. With a follow-up of 3 years, we estimate that only 12 and 33 patients per arm are needed to show stabilisation of MRI lesion load in the RRMS and SPMS groups, respectively. Our results suggest that ongoing phase III treatment trials are more than adequately powered to detect even subtle treatment effects, and indicate that incorporating measurements from longer follow-up durations increases power substantially. We conclude that an annual imaging protocol provides a robust and powerful tool for assessing effects on the radiological appearance of the disease process.

AB - Phase III definitive treatment trials of new multiple sclerosis (MS) therapies now routinely incorporate an annual magnetic resonance imaging protocol, with change in T2-weighted brain lesion load providing an important outcome measure. To date the accepted strategy has been to perform a core imaging protocol on all patients in such studies. The aim of this study was to provide power calculations based on this MRT endpoint. Serial MRI data from 128 patients with either relapsing remitting (RR) or secondary progressive (SP) MS were used to calculate sample size requirements using a repeated measures analysis of variance design. We provide sample size calculations based on various follow-up intervals and effect sizes. Sample sizes for the SPMS cohort were substantially larger than for the RRMS group, reflecting the greater variance in lesion load changes between patients in the SPMS group. With a follow-up of 3 years, we estimate that only 12 and 33 patients per arm are needed to show stabilisation of MRI lesion load in the RRMS and SPMS groups, respectively. Our results suggest that ongoing phase III treatment trials are more than adequately powered to detect even subtle treatment effects, and indicate that incorporating measurements from longer follow-up durations increases power substantially. We conclude that an annual imaging protocol provides a robust and powerful tool for assessing effects on the radiological appearance of the disease process.

KW - Multiple sclerosis

KW - Power calculations

KW - Treatment trial

UR - http://www.scopus.com/inward/record.url?scp=0034104977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034104977&partnerID=8YFLogxK

M3 - Article

VL - 247

SP - 34

EP - 40

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 1

ER -